ICOS/NFAT Reporter-Jurkat Recombinant Cell Line

Catalog #

79668

$10,340 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of a chimeric receptor consisting human ICOS (also known as inducible T-cell costimulator or CD278, Genbank Accession #NM_012092) and the cytoplasmic domain of human CD3 zeta.

Assay Principle

Interested in screening and profiling inhibitors, blocking antibodies, or activators of ICOS without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

T-cell costimulator, CD278

●

Product Data Gallery

The ICOS/NFAT Reporter Activities Stimulated by ICOSL-CHO Cells

Dose response of anti-ICOS agonist antibody on ICOS/NFAT Reporter-Jurkat cells

FACS Analysis of Cell Surface Expression of ICOS in ICOS/NFAT Reporter-Jurkat cells

Product Info

Storage and Usage

Citations

Host Cell Line

Jurkat T Cell

Materials Required But Not Supplied

• Assay Medium: Thaw Medium 2 (BPS Bioscience #60184)

• ICOSL-CHO K1 Recombinant Cell Line (BPS Bioscience #79635) and its recommended growth medium (Growth Medium 3D, BPS Bioscience #79539)

• 96-well tissue culture-treated white clear-bottom assay plate

• One-Step luciferase assay system (BPS Bioscience #60690) for measuring firefly luciferase activity

• Luminometer

Format

Each vial contains 2 x 10⁶ cells in 1 ml of 10% DMSO in FBS.

UniProt #

Q9Y6W8

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination.

Background

ICOS is a costimulatory molecule of the CD28 cell surface receptor superfamily that is expressed on activated T-cells. ICOS is involved in T-cell responses upon binding with its ligand, ICOSL (also known as B7-H2, CD275), which is normally expressed on B-cells, dendritic cells and monocytes. ICOS expression confers an activated phenotype and a strong suppressive capacity to intra-tumoral regulatory T-cells. The ICOS/ICOSL pathway is a key target for cancer immunotherapy.

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 2 (BPS Bioscience #60184): RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 2F (BPS Bioscience #79669): RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin, 1 mg/ml of Geneticin, and 0.5 μg/ml of Puromycin

Instructions for Use

See data sheet for detailed culturing and assay protocol.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles.

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only